Patents by Inventor Paul Delmar

Paul Delmar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Predictive marker for EGFR inhibitor treatment
    Patent number: 9121067
    Abstract: The present invention provides a biomarker which is predictive for the clinical benefit of EGFR inhibitor treatment in cancer patients.
    Type: Grant
    Filed: April 1, 2013
    Date of Patent: September 1, 2015
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Paul Delmar, Barbara Klughammer, Verena Lutz, Patricia McLoughlin
  • BLOOD PLASMA BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES FOR TREATMENT OF PANCREATIC CANCER
    Publication number: 20140302019
    Abstract: The present invention provides methods for improving the treatment effect of a chemotherapy regimen of a patient suffering from pancreatic cancer, in particular metastatic pancreatic cancer by adding bevacizumab (Avastin®) to a chemotherapy regimen by determining the expression level, in particular the blood plasma expression level, of one or more of VEGFA, VEGFR2 and PLGF relative to control levels of patients diagnosed with pancreatic cancer, in particular metastatic pancreatic cancer. In particular, the present invention provides methods of improving the treatment effect, wherein the treatment effect is the overall survival and/or progression-free survival of the patient.
    Type: Application
    Filed: June 20, 2014
    Publication date: October 9, 2014
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Paul DELMAR, Dorothee FOERNZLER, Friedemann KRAUSE, Stefan SCHERER
  • METHOD FOR PREDICTING RISK OF HYPERTENSION ASSOCIATED WITH ANTI-ANGIOGENESIS THERAPY
    Publication number: 20140294811
    Abstract: The invention is concerned with a method of predicting a patient's susceptibility to developing hypertension associated with an anti-angiogenesis treatment, such as bevacizumab, by determining the genotype of KDR gene and/or EGF gene. The invention further relates to a pharmaceutical composition comprising an angiogenesis inhibitor, such as bevacizumab, for the treatment of a patient suffering from cancer based on the genotype of KDR gene and/or EGF. The invention further relates to a method for reducing the risk of hypertension associated with an anti-angiogenesis therapy, such as bevacizumab, in a patient suffering from cancer by determining the genotype of KDR gene and/or EGF gene.
    Type: Application
    Filed: February 26, 2014
    Publication date: October 2, 2014
    Applicants: Hoffmann-La Roche Inc., VIB vzw, Life Sciences Research Partners vzw
    Inventors: Sanne Lysbet de Haas, Paul Delmar, Diether Lambrechts, Stefan Scherer
  • RESPONSIVENESS TO ANGIOGENESIS INHIBITORS
    Publication number: 20140294768
    Abstract: The invention is concerned with a method of determining whether a patient is more suitably treated by a therapy with an angiogenesis inhibitor, such as bevacizumab, by determining the genotype of VEGF promoter gene and/or VEGFR2 gene. The invention further relates to a pharmaceutical composition comprising an angiogenesis inhibitor, such as bevacizumab, for the treatment of a patient suffering from cancer based on the genotype of VEGF promoter gene and/or VEGFR2 gene. The invention further relates to a method for improving the treatment effect of chemotherapy of a patient suffering from cancer by adding an angiogenesis inhibitor, such as bevacizumab, based on the genotype of VEGF promoter gene and/or VEGFR2 gene.
    Type: Application
    Filed: February 26, 2014
    Publication date: October 2, 2014
    Inventors: Sanne Lysbet de Haas, Paul Delmar, Diether Lambrechts, Stefan Scherer
  • METHODS TO IDENTIFY RESPONSIVE PATIENTS
    Publication number: 20140099302
    Abstract: The present invention provides methods and kits for improving the progression-free survival of a patient suffering from gastrointestinal cancer and for assessing the sensitivity or responsiveness of the patient to treatment comprising bevacizumab.
    Type: Application
    Filed: October 4, 2013
    Publication date: April 10, 2014
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Paul Delmar, Dorothee Foernzler, Stefan Scherer
  • METHODS AND COMPOSITIONS FOR DIAGNOSTIC USE IN CANCER PATIENTS
    Publication number: 20130315899
    Abstract: Disclosed herein are methods and compositions useful for identifying therapies likely to confer optimal clinical benefit for patients with cancer.
    Type: Application
    Filed: May 23, 2013
    Publication date: November 28, 2013
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Sanne Lysbet De Haas, Stefan Scherer, Paul Delmar
  • RESPONSIVENESS TO ANGIOGENESIS INHIBITORS
    Publication number: 20120195858
    Abstract: The present invention relates to methods for improving the overall survival of a patient suffering from a malignant disease or a disease involving physiological and pathological angiogenesis by treatment with an angiogenesis inhibitor, such as bevacizumab, by determining the presence of one or more variant alleles of the vascular endothelial growth factor receptor 1 (VEGFR-1) gene. The present invention further provides methods for improving the progression-free survival of a patient suffering from a malignant disease or a disease involving physiological and pathological angiogenesis by treatment with an angiogenesis inhibitor, such as bevacizumab, by determining the presence of one or more variant alleles of the VEGFR-1 gene. The present invention also provides for methods for assessing the responsiveness of a patient to an angiogenesis inhibitor by determining the presence of one or more variant alleles of the VEGFR-1 gene.
    Type: Application
    Filed: August 3, 2010
    Publication date: August 2, 2012
    Inventors: Dorothee Foernzler, Paul Delmar, Stefan Scherer, Diether Lambrechts, Peter Carmeliet
  • METHODS FOR DETECTING LOW GRADE INFLAMMATION
    Publication number: 20120164639
    Abstract: The present invention relates to methods for detecting the presence of low grade inflammation in a patient.
    Type: Application
    Filed: November 23, 2011
    Publication date: June 28, 2012
    Inventors: MARIA BOBADILLA, PAUL DELMAR, GUILLEMETTE DUCHATEAU-NGUYEN, STANLEY LAZIC, MARIA CHIARA MAGNONE, TRI QUANG NGUYEN
  • PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT
    Publication number: 20110312981
    Abstract: The present invention provides a biomarker SFRS7 which is predictive for the clinical benefit of EGFR inhibitor treatment in cancer patients.
    Type: Application
    Filed: August 7, 2008
    Publication date: December 22, 2011
    Inventors: Paul Delmar, Barbara Klughammer, Verena Lutz, Patricia McLoughlin
  • PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT
    Publication number: 20110245279
    Abstract: The present invention provides a biomarker which is predictive for the clinical benefit of EGFR inhibitor treatment in cancer patients
    Type: Application
    Filed: August 7, 2008
    Publication date: October 6, 2011
    Inventors: Paul Delmar, Barbara Klughammer, Verena Lutz, Patricia McLoughlin
  • PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT
    Publication number: 20110230506
    Abstract: The present invention provides a biomarker (RAPGEF5) that is predictive for the response to treatment with an EGFR inhibitor in cancer patients.
    Type: Application
    Filed: August 7, 2008
    Publication date: September 22, 2011
    Inventors: Paul Delmar, Barbara Klughammer, Verena Lutz, Patricia McLoughlin
  • PREDICTIVE MARKERS FOR EGFR INHIBITORS TREATMENT
    Publication number: 20110218212
    Abstract: The present invention provides biomarkers that are predictive for the response to treatment with an EGFR inhibitor in cancer patients. The markers are the genes GBAS, APOH, SCYL3, PMS2CL, PRODH, SERF1A, URG4A and LRRC31.
    Type: Application
    Filed: August 7, 2008
    Publication date: September 8, 2011
    Inventors: Paul Delmar, Barbara Klughammer, Verna Lutz, Patricia McLoughlin
  • PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT
    Publication number: 20110212979
    Abstract: The present invention provides a biomarker which is predictive for the clinical benefit of EGFR inhibitor treatment in cancer patients.
    Type: Application
    Filed: August 7, 2008
    Publication date: September 1, 2011
    Inventors: Paul Delmar, Barbara Klughammer, Verena Lutz, Patricia McLoughlin
  • PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT
    Publication number: 20110195982
    Abstract: The present invention provides a biomarker that is predictive for the response to treatment with an EGFR inhibitor in cancer patients
    Type: Application
    Filed: August 7, 2008
    Publication date: August 11, 2011
    Inventors: Paul Delmar, Barbara Klughammer, Verena Lutz, Patricia McLoughlin
  • PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT
    Publication number: 20110190321
    Abstract: The present invention provides a biomarker that is predictive for the response to treatment with an EGFR inhibitor in cancer patients.
    Type: Application
    Filed: August 7, 2008
    Publication date: August 4, 2011
    Inventors: Paul Delmar, Barbara Kiughammer, Verena Lutz, Patricia McLoughlin
  • Methods to identify responsive patients
    Publication number: 20110182892
    Abstract: The present invention provides methods and kits for improving the progression-free survival of a patient suffering from gastrointestinal cancer and for assessing the sensitivity or responsiveness of the patient to treatment comprising bevacizumab.
    Type: Application
    Filed: January 18, 2011
    Publication date: July 28, 2011
    Applicant: Hoffman-La Roche. Inc.
    Inventors: Paul Delmar, Dorothee Foernzler, Stefan Scherer
  • PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT
    Publication number: 20110184004
    Abstract: The present invention provides biomarkers which are predictive for the clinical benefit of EGFR inhibitor treatment in cancer patients.
    Type: Application
    Filed: August 7, 2008
    Publication date: July 28, 2011
    Inventors: Paul Delmar, Barbara Klughammer, Verena Lutz, Patricia McLoughlin
  • PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT
    Publication number: 20110184005
    Abstract: The present invention provides a biomarker which is predictive for the clinical benefit of EGFR inhibitor treatment in cancer patients.
    Type: Application
    Filed: August 7, 2008
    Publication date: July 28, 2011
    Inventors: Paul Delmar, Barbara Klughammer, Verena Lutz, Patricia McLoughlin
  • METHODS AND COMPOSITIONS FOR DIAGNOSTIC USE IN CANCER PATIENTS
    Publication number: 20110064732
    Abstract: Disclosed herein are methods and compositions useful for identifying therapies likely to confer optimal clinical benefit for patients with cancer.
    Type: Application
    Filed: September 16, 2010
    Publication date: March 17, 2011
    Inventors: Sanne Lysbet De Haas, Paul Delmar, Stefan Scherer